FOSUN PHARMA
复兴医药
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock codes: 600196.SH, 02196.HK) was established in 1994. It is an innovation-driven global pharmaceutical and health industry group rooted in China. Its directly operated businesses cover pharmaceuticals, medical devices and diagnostics, and medical health services. Through equity participation in Sinopharm Holdings, it also encompasses the pharmaceutical commerce field.
Centering on patients and guided by clinical needs, Fosun Pharma continuously enriches its innovative product pipeline through independent R&D, collaborative development, licensed introduction, and deep incubation. It enhances its research and clinical development capabilities for First-in-class (FIC) and Best-in-class (BIC) drugs, accelerating the research, development, and implementation of innovative technologies and products.
Under the strategic guidance of “4IN” (Innovation, Internationalization, Intelligentization, Integration), Fosun Pharma adheres to a development model of “innovative transformation, integrated operation, and steady growth.” It constantly strengthens independent R&D and external cooperation, enhances its product lineup, intensifies its global footprint, and boosts operational efficiency. Furthermore, it actively advances both online and offline deployments in the medical health industry, aiming to become a top-tier enterprise in the global medical health market.
Fosun Pharma strategically covers the entire health industry chain, operating directly in the fields of pharmaceuticals, medical devices and diagnostics, and medical services. It also covers the pharmaceutical commerce domain through its stake in Sinopharm Holdings.
In 2020, Fosun Pharma achieved a revenue of RMB 303.07 billion, a year-on-year increase of 6.02%. The net profit attributable to the listed company’s shareholders was RMB 36.63 billion, up by 10.27% year-on-year. The non-recurring profit attributable to shareholders was RMB 27.18 billion, a year-on-year surge of 21.65%.
Fosun Pharma boasts a range of leading products in areas like metabolism and digestive systems, anti-tumor, anti-infection, central nervous system, and cardiovascular system. Hanlikang (Rituximab injection) saw its production scale approved to increase to 2,000L, achieving a total revenue of RMB 7.5 billion in 2020. The newly launched products in August 2020, Sukoxin (Apremilast tablets) and Hanquyou (Trastuzumab injection), quickly gained market access and actively pushed for inclusion in China’s national and provincial medical insurance directories, each achieving a revenue of around RMB 1.4 billion.
In 2020, Fosun Pharma’s core pharmaceutical business achieved a turnover of RMB 218.8 billion. R&D investment in this sector was RMB 36.70 billion, an increase of 17.21% year-on-year, accounting for 16.77% of the revenue. Among this, R&D expenses reached RMB 24.68 billion, a rise of RMB 7.27 billion or 41.76% year-on-year, making up 11.28% of the revenue.
On June 17, 2022, Fosun Pharma announced that its subsidiary, Shanghai Henlius Biotech, initiated Phase III clinical trials in mainland China (excluding Hong Kong, Macao, and Taiwan) for its self-developed recombinant anti-RANKL monoclonal antibody injection (HLX14) for treating postmenopausal osteoporosis in high-risk fracture women.
On October 17, 2022, Fosun Pharma announced that it received approval from Chinese national authorities to start clinical trials for its self-developed HLX60, a recombinant anti-GARP humanized monoclonal antibody injection for the treatment of solid tumors and lymphomas. Henlius plans to initiate Phase I clinical trials for this new drug in mainland China (excluding Hong Kong, Macao, and Taiwan) once conditions are met.
Fosun Pharma’s medical devices and diagnostics sector offers a broad professional coverage. Through business integration and synergy, it has preliminarily formed three main business branches: medical aesthetics, respiratory health, and specialized medical services.
Its diagnostics business has a wide layout, a rich product line, and integrated capabilities in R&D, manufacturing, marketing, BD, and investment. The products span clinical chemistry, clinical immunology, molecular diagnostics, microbiology, POCT [58], and other areas of laboratory medicine. They revolve around six major disease areas, including oncology, metabolic diseases, cardiovascular and cerebrovascular diseases, reproduction, central nervous system, and infections, forming a range of large-scale automated assembly lines and small-scale POCT product groups.
In 2020, Fosun Pharma’s medical devices and diagnostics business achieved a revenue of RMB 52.17 billion, an increase of 39.64% year-on-year. The segment’s performance reached RMB 10.53 billion, up 83.45% year-on-year, with a profit of RMB 9.07 billion, a year-on-year growth of 83.23%.
Fosun Health is a health services industry platform supported by comprehensive and specialized medical care. Since 2010, it has focused on the Greater Bay Area, Yangtze River Delta, Huaihai Economic Region, and Chengdu-Chongqing Economic Zone, forming a strategic layout combining specialized and comprehensive hospitals. Upholding the philosophy of “caring for life, safeguarding health,” Fosun Health always prioritizes patient interests. Through offering internationally acclaimed professional techniques, innovative services, and health management, it aims to earn respect for its medical endeavors, ensure every family’s health, and strives to become a global leader in serving families’ health. By the end of 2020, Fosun Pharma Group controlled over ten medical service institutions, with a total of 4,610 approved beds.
Through its stake in Sinopharm Holdings, Fosun Pharma extends its reach to the pharmaceutical commercial sector. In 2003, Fosun Pharma and Sinopharm Group jointly established Sinopharm Holdings, a leading distributor of drugs and healthcare products in China and a top supply chain service provider. In 2020, Sinopharm Holdings achieved a turnover of RMB 4,564.15 billion, with a net profit of RMB 120.97 billion and an attributable net profit of RMB 71.87 billion. It operated a total of 8,977 retail stores.
